|
|
Redsense blood spill detector gets FDA clearance for clinical use. |
|
PR Newswire (Redsense) : The Redsense safety device is the only device cleared by FDA to monitor patients for potential blood loss from the hemodialysis needle puncture site. With an 8 hour FDA clinical clearance, Redsense is available to help protect patients undergoing treatment in clinics for longer than 5 hours - such as Nocturnal Dialysis.
|
|
|
NxStage Medical, Inc. (NXTM) is reiterated as a “Mkt Underperform” rating by ... - FavStocks |
FavStocks
NxStage Medical, Inc. is a medical device company, headquartered in Lawrence, Massachusetts, USA, that develops, manufactures and markets innovative systems for the treatment of end-stage renal disease, or ESRD, and acute kidney failure.
|
|
Nocturnal Dialysis - FDA Clears the Redsense Safety Device for 8 Hours - PR Newswire (press release) |
PR Newswire (press release)
With an 8 hour FDA clinical clearance, Redsense is available to help protect patients undergoing treatment in clinics for longer than 5 hours - such as Nocturnal Dialysis. Dialysis equipment today is required to have a system that protects patients
|
|
Research and Markets: Renal Cell Carcinoma (RCC) Therapeutics - Pipeline ... - Business Wire (press release) |
Business Wire (press release)
Renal Cell Carcinoma (RCC) Therapeutics - Pipeline Assessment and Market Forecasts to 2017 is an essential source of information and analysis on the global renal cell carcinoma therapeutics market. The report identifies the key trends shaping and
|
|
Degarelix Superior to Leuprolide, Study Finds - Renal and Urology News |
Renal and Urology News
“The long-term data support the durability of the significant progression-free survival benefit for degarelix treatment over monthly leuprolide seen during the first treatment year,” Dr. Shore told Renal & Urology News. Additionally, he noted, these
|
|
|
|
|
<< Start < Prev 1061 1062 1063 1064 1065 1066 1067 1068 1069 1070 Next > End >>
|
|
Page 1068 of 2630 |